ÖÐÎÄÃû³Æ£º Íÿ¹MLANA¶à¿Ë¡¿¹Ìå
Ó¢ÎÄÃû³Æ£º Anti-MLANA rabbit polyclonal antibody
±ð Ãû£º MART1; MART-1
Ïà¹ØÀà±ð£º Ò»¿¹
´¢ ´æ£º Àä¶³£¨-20¡æ£©
ËÞ Ö÷£º Rabbit
¿¹ Ô£º MLANA
·´Ó¦ÖÖÊô£º Human
±ê ¼Ç Î Unconjugate
¿Ë¡ÀàÐÍ£º rabbit polyclonal
¼¼Êõ¹æ¸ñ
|
Background: |
Melan-A (also designated MART-1) is a melanocyte differentiation antigen that is specific to melanomas, melanocyte cell lines and retina. Melan-A peptide is recognized by most HLA-A2-restricted tumor-specific tumor-infiltrating lymphocytes in patients with melanoma. Antimelanoma cytotoxic T lymphocytes can be generated with a Melan-A peptide, implicating Melan-A as a potential candidate for antigen-specific immunotherapy in melanoma patients. Involved in melanosome biogenesis by ensuring the stability of GPR143. Plays a vital role in the expression, stability, trafficking, and processing of melanocyte protein PMEL, which is critical to the formation of stage II melanosomes. |
|
Applications: |
ELISA, IHC |
|
Name of antibody: |
MLANA |
|
Immunogen: |
Synthetic peptide of human MLANA |
|
Full name: |
melan-A |
|
Synonyms: |
MART1; MART-1 |
|
SwissProt: |
Q16655 |
|
ELISA Recommended dilution: |
5000-10000 |
|
IHC positive control: |
Human esophagus cancer |
|
IHC Recommend dilution: |
40-250 |

¹ºÎï³µ
°ïÖú
021-54845833/15800441009
